What is Neoleukin Therapeutics' stock price target for 2024?

0 brokerages have issued twelve-month price objectives for Neoleukin Therapeutics' stock. Their NLTX share price targets range from $30.00 to $30.00. On average, they predict the company's share price to reach $30.00 in the next twelve months. This suggests that the stock has a possible downside of 5.0%. View analysts price targets for NLTX or view top-rated stocks among Wall Street analysts .

How have NLTX shares performed in 2024?

Neoleukin Therapeutics' stock was trading at $19.38 at the start of the year. Since then, NLTX shares have increased by 63.0% and is now trading at $31.58. View the best growth stocks for 2024 here .

How were Neoleukin Therapeutics' earnings last quarter?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($5.60) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($5.60).

When did Neoleukin Therapeutics' stock split?

Neoleukin Therapeutics shares reverse split on Tuesday, December 19th 2023. The 1-4 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Neoleukin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA) , Cisco Systems (CSCO) , Pfizer (PFE) , RTX (RTX) , Procter & Gamble (PG) , Sorrento Therapeutics (SRNE) , CVS Health (CVS) , Fulcrum Therapeutics (FULC) and Home Depot (HD) .

How do I buy shares of Neoleukin Therapeutics?

Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NLTX

Neoleukin Therapeutics (NLTX) Stock Price, News & Analysis

→ The #1 Crypto for 2024 (From InvestorPlace) (Ad)

Free NLTX Stock Alerts

$31.58

-2.06 (-6.12%)

(As of 04/18/2024 ET)

Compare

Today's Range: $30.85
▼
$33.81
50-Day Range: $13.96
▼
$50.90
52-Week Range: $2.03
▼
$14.36

Volume: 100,284 shs
Average Volume: 50,104 shs
Market Capitalization: $296.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.00

Get Neoleukin Therapeutics alerts:

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About Neoleukin Therapeutics Stock (NASDAQ:NLTX)

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

NLTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NLTX Stock News Headlines

December 20, 2023 | finance.yahoo.com

Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?

December 15, 2023 | finance.yahoo.com

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

April 19, 2024 | InvestorPlace (Ad)

The #1 Crypto for 2024

5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.

December 4, 2023 | benzinga.com

Neoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and Dates

October 5, 2023 | markets.businessinsider.com

Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…

September 26, 2023 | finanznachrichten.de

Neoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

September 22, 2023 | finance.yahoo.com

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

August 18, 2023 | benzinga.com

Neoleukin Therapeutics Recent Insider Activity

April 19, 2024 | InvestorPlace (Ad)

The #1 Crypto for 2024

August 18, 2023 | finance.yahoo.com

BAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics Inc

August 8, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCU

August 1, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTX

July 28, 2023 | finance.yahoo.com

Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc

July 26, 2023 | benzinga.com

Moore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law Firm

July 24, 2023 | 247wallst.com

Baker Bros. Advisors Now Owns 19.99% of Neoleukin Therapeutics

July 19, 2023 | markets.businessinsider.com

Neurogene, Neoleukin Announce Planned Merger

July 18, 2023 | msn.com

Univ. of Washington spinout Neoleukin Therapeutics merging with New York City startup

July 18, 2023 | finanznachrichten.de

Neoleukin Therapeutics, Inc.: Neurogene and Neoleukin Announce Definitive Merger Agreement

July 18, 2023 | benzinga.com

Neoleukin Therapeutics To Merge With Neurogene: Creates Biotech Firm Focused On Genetic Medicines For Neurological Diseases

July 18, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, NLTX, FREQ

July 18, 2023 | msn.com

Neoleukin jumps 7% on Neurogene merger

July 18, 2023 | marketwatch.com

Neoleukin Therapeutics Shares Rise Premarket on Reverse Merger Deal >NLTX

July 18, 2023 | technews.tmcnet.com

NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders

July 18, 2023 | finance.yahoo.com

Neurogene and Neoleukin Announce Definitive Merger Agreement

May 23, 2023 | finance.yahoo.com

Biomed Industries, Inc. Offers to acquire Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)

May 9, 2023 | markets.businessinsider.com

Mizuho Securities Reaffirms Their Hold Rating on Neoleukin Therapeutics (NLTX)

April 7, 2023 | bizjournals.com

Neoleukin Therapeutics promotes general counsel to interim CEO

See More Headlines

Receive NLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NLTX
CUSIP: N/A
CIK: 1404644
Web: www.neoleukin.com
Phone: (866) 245-0312
Fax: 778-331-4486
Employees: 7
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $30.00
High Stock Price Target: $30.00
Low Stock Price Target: $30.00
Potential Upside/Downside: -5.0%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-57,560,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -37.22%
Return on Assets: -30.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.33
Quick Ratio: 15.33

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.08 per share
Price / Book: 2.85

Miscellaneous

Outstanding Shares: 9,398,000
Free Float: 9,250,000
Market Cap: $296.79 million
Optionable: Optionable
Beta: 1.11

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Ms. Donna M. Cochener-Metcalfe J.D. (Age 48)
General Counsel, Interim CEO & Corporate Secretary
Comp: $403.75k
Dr. David Baker M.D.
Ph.D., Co-Founder
Mr. Sean Michael Smith (Age 37)
Interim Chief Financial Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

NLTX Stock Analysis - Frequently Asked Questions

What is Neoleukin Therapeutics' stock price target for 2024?: 0 brokerages have issued twelve-month price objectives for Neoleukin Therapeutics' stock. Their NLTX share price targets range from $30.00 to $30.00. On average, they predict the company's share price to reach $30.00 in the next twelve months. This suggests that the stock has a possible downside of 5.0%.
View analysts price targets for NLTX or view top-rated stocks among Wall Street analysts.
How have NLTX shares performed in 2024?: Neoleukin Therapeutics' stock was trading at $19.38 at the start of the year. Since then, NLTX shares have increased by 63.0% and is now trading at $31.58.
View the best growth stocks for 2024 here.
How were Neoleukin Therapeutics' earnings last quarter?: Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($5.60) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($5.60).
When did Neoleukin Therapeutics' stock split?: Neoleukin Therapeutics shares reverse split on Tuesday, December 19th 2023. The 1-4 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Neoleukin Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), RTX (RTX), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and Home Depot (HD).
How do I buy shares of Neoleukin Therapeutics?: Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NLTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial